Rapid decline of neutralizing antibodies against SARS-CoV-2 among infected healthcare workers
| Autor: | Marot, Stéphane, Malet, Isabelle, Leducq, Valentin, Zafilaza, Karen, Sterlin, Delphine, Planas, Delphine, Gothland, Adélie, Jary, Aude, Dorgham, Karim, Bruel, Timothée, Attali, Valérie, Baresse, Isabelle, Beurton, Alexandra, Boddaert, Jacques, Bourmaleau, Julie, Catala, Martin, Demoule, Alexandre, Dunoyer, Violaine, Esteban-Amarilla, Cristina, Hausfater, Pierre, Haziot, Noémie, Ip, Queyras, Kubis, Nathalie, Lhoest, Laurence, Lubetzki, Catherine, Marion, Fabienne, Morawiec, Elise, Mourtada, Leila, Orcel, Brigitte, Morelot-Panzini, Capucine, Raux, Mathieu, Reinhard, Christophe, Riquier, Claire, Roubertier, Xavier, Weiss, Nicolas, Zalc, Bernard, Burrel, Sonia, Boutolleau, David, Schwartz, Olivier, Gorochov, Guy, Calvez, Vincent, Marcelin, Anne-Geneviève |
|---|---|
| Přispěvatelé: | Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU), Anticorps en thérapie et pathologie - Antibodies in Therapy and Pathology, Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut Pasteur [Paris], Centre d'Immunologie et de Maladies Infectieuses (CIMI), Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS), Vaccine Research Institute (VRI), Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Virus et Immunité - Virus and immunity, Institut Pasteur [Paris]-Centre National de la Recherche Scientifique (CNRS), The AGM laboratory is funded by Agence Nationale de Recherches sur le SIDA et les hépatites virales (AC43, Medical Virology), the SARS-CoV-2 Program of the Faculty of Medicine of Sorbonne University, the Agence Nationale de la Recherche. The GG laboratory is supported by the Fondation de France, 'Tous unis contre le virus' framework Alliance (Fondation de France, AP-HP, Institut Pasteur) in collaboration with the Agence Nationale de la Recherche (ANR Flash COVID19 program) and by the SARS-CoV-2 Program of the Faculty of Medicine of Sorbonne University ICOViD programs. The OS laboratory is funded by Institut Pasteur, the ANRS, the Vaccine Research Institute (ANR-10-LABX-77), Labex IBEID (ANR-10-LABX-62-IBEID), 'TIMTAMDEN' ANR-14-CE14-0029, 'CHIKV-Viro-Immuno' ANR-14-CE14-0015-01, the Gilead HIV cure program, ANR/FRM Flash Covid PROTEO-SARS-CoV-2 and IDISCOVR, and Fondation pour la Recherche Médicale. We thank Nathalie Aulner and the UtechS Photonic BioImaging (UPBI) core facility (Institut Pasteur), a member of the France BioImaging network, for image acquisition and analysis., ANR-10-LABX-0062,IBEID,Integrative Biology of Emerging Infectious Diseases(2010), ANR-10-LABX-0077,VRI,Initiative for the creation of a Vaccine Research Institute(2010), ANR-14-CE14-0029,TIMTAMDEN,Rôle des récepteurs TIM et TAM dans l'infection des cellules cibles par le virus de la dengue(2014), ANR-14-CE14-0015,CHIKV-Viro-Immuno,Multiplication et Relation avec l'hôte du virus Chikungunya(2014), Institut Pasteur [Paris]-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre d'Immunologie et des Maladies Infectieuses (CIMI), Institut Pasteur [Paris] (IP)-Institut National de la Santé et de la Recherche Médicale (INSERM), Vaccine Research Institute [Créteil, France] (VRI), Virus et Immunité - Virus and immunity (CNRS-UMR3569), Institut Pasteur [Paris] (IP)-Centre National de la Recherche Scientifique (CNRS), HAL-SU, Gestionnaire, Integrative Biology of Emerging Infectious Diseases - - IBEID2010 - ANR-10-LABX-0062 - LABX - VALID, Laboratoires d'excellence - Initiative for the creation of a Vaccine Research Institute - - VRI2010 - ANR-10-LABX-0077 - LABX - VALID, Appel à projets générique - Rôle des récepteurs TIM et TAM dans l'infection des cellules cibles par le virus de la dengue - - TIMTAMDEN2014 - ANR-14-CE14-0029 - Appel à projets générique - VALID, Appel à projets générique - Multiplication et Relation avec l'hôte du virus Chikungunya - - CHIKV-Viro-Immuno2014 - ANR-14-CE14-0015 - Appel à projets générique - VALID |
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
0301 basic medicine
Immunoglobulin A Coronavirus disease 2019 (COVID-19) Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Science General Physics and Astronomy [SDV.IMM.II]Life Sciences [q-bio]/Immunology/Innate immunity Article General Biochemistry Genetics and Molecular Biology Persistence (computer science) 03 medical and health sciences 0302 clinical medicine [SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases Medicine Infection control 030212 general & internal medicine [SDV.IMM.II] Life Sciences [q-bio]/Immunology/Innate immunity [SDV.MHEP.ME] Life Sciences [q-bio]/Human health and pathology/Emerging diseases [SDV.MHEP.ME]Life Sciences [q-bio]/Human health and pathology/Emerging diseases Multidisciplinary [SDV.MHEP] Life Sciences [q-bio]/Human health and pathology biology business.industry SARS-CoV-2 General Chemistry biochemical phenomena metabolism and nutrition 3. Good health Vaccination Titer 030104 developmental biology Viral infection Immunology biology.protein [SDV.MHEP.MI] Life Sciences [q-bio]/Human health and pathology/Infectious diseases sense organs Antibody business [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology |
| Zdroj: | Nature Communications Nature Communications, Nature Publishing Group, 2021, 12 (1), pp.844. ⟨10.1038/s41467-021-21111-9⟩ Nature Communications, 2021, 12 (1), pp.844. ⟨10.1038/s41467-021-21111-9⟩ Nature Communications, Vol 12, Iss 1, Pp 1-7 (2021) |
| ISSN: | 2041-1723 |
| DOI: | 10.1038/s41467-021-21111-9⟩ |
| Popis: | There are only few data concerning persistence of neutralizing antibodies (NAbs) among SARS-CoV-2-infected healthcare workers (HCW). These individuals are particularly exposed to SARS-CoV-2 infection and at potential risk of reinfection. We followed 26 HCW with mild COVID-19 three weeks (D21), two months (M2) and three months (M3) after the onset of symptoms. All the HCW had anti-receptor binding domain (RBD) IgA at D21, decreasing to 38.5% at M3 (p The humoral immune response to SARS-CoV-2 infection is not yet fully understood. Here, Marot et al. monitor the longitudinal profile and neutralizing activity of IgG, IgA, and IgM among 26 healthcare workers and provide evidence for a short-lasting humoral immune protection due to a decrease of neutralizing antibody titers within 3 months. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|